Vigil Neuroscience Announced An Update Following A Type C Meeting With The FDA To Its Clinical Development Strategy For Its IGNITE Trial Of Iluzanebart For Adult-onset Leukoencephalopathy With Axonal Spheroids And Pigmented Glia
Portfolio Pulse from Benzinga Newsdesk
Vigil Neuroscience announced an update to its clinical development strategy for the IGNITE trial of iluzanebart following a Type C meeting with the FDA. The final analysis, including all patients dosed at 12 months, will be reported in the first half of 2025.
July 18, 2024 | 11:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vigil Neuroscience provided an update on its IGNITE trial for iluzanebart after a Type C meeting with the FDA. The final analysis will be reported in the first half of 2025.
The update indicates progress in the clinical trial process, which is generally positive news for the company. The final analysis timeline provides a clear milestone for investors to watch.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100